Development of Albumin Nanocarriers for Enhanced Curcumin Delivery and In Vitro Anticancer Activity in Colon Cancer Cells
Pharmaceuticals · 30.05.2026 · 19 (6) · 872
DOI: 10.3390/ph19060872 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 30.05.2026. Verfasst von Aftab Ahmad und 6 weiteren Autor:innen. Beteiligte Einrichtung: Health Information Technology Department, The Applied College, King Abdulaziz University, Jeddah 21589, Saudi Arabia. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Ministry of Education and King Abdulaziz University, DSR, Jeddah, Saudi Arabia., Institutional Fund Projects, The Ministry of Education and King Abdulaziz University, DSR, Jeddah, Saudi Arabia.
Abstract (Originalsprache)
Objectives
Curcumin possesses well-documented anticancer activity; however, its clinical translation is hindered by poor aqueous solubility and limited bioavailability. The present study aimed to engineer pH-dependent bovine serum albumin (BSA)–based nanocarriers for curcumin delivery and to evaluate their physicochemical characteristics, controlled release behavior under gastrointestinal pH conditions, and in vitro anticancer efficacy against the human colon cancer cell line Colo-205.
Methods
Curcumin-loaded bovine serum albumin nanoparticles (Cu-BSA-NPs) were fabricated using a desolvation technique followed by chemical crosslinking. Particle size, zeta potential, and polydispersity index (PDI) were assessed by dynamic light scattering. Morphology was examined using scanning electron microscopy (SEM), while structural and thermal properties were evaluated by Fourier-transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC). Drug loading capacity and entrapment efficiency were quantified spectrophotometrically. In vitro drug release was investigated using a gastrointestinal pH-transition model (pH 1.2, 6.8, and 7.4). Cytotoxic activity was assessed using the sulforhodamine B (SRB) assay on Colo-205 cells.
Results
The engineered Cu-BSA-NPs exhibited particle sizes ranging from 96.7 ± 10.5 to 126.4 ± 35.8 nm, with PDI values between 0.289 and 0.581 and zeta potentials from −18.2 ± 1.01 to −34 ± 1.0 mV, indicating nanoscale dimensions and moderate colloidal stability. SEM analysis revealed spherical nanoparticles with smooth surfaces and uniform morphology. Entrapment efficiency ranged from 6.59 ± 1.11% to 52.98 ± 0.65%, while drug loading efficiency varied between 1.308 ± 0.206% and 16.744 ± 0.266%. In vitro release studies demonstrated minimal drug release under acidic (pH 1.2) and near-neutral (pH 6.8) conditions, followed by significantly enhanced release at pH 7.4, confirming pH-dependent behavior of the albumin matrix. Cytotoxicity studies showed significant antiproliferative activity against Colo-205 human colon cancer cells.
Conclusions
The findings demonstrate successful engineering of albumin-based nanocarriers capable of modulating curcumin release under physiologically relevant pH conditions and enhancing in vitro anticancer activity. Although limited to in vitro evaluation, this study highlights the potential of protein-based nanoplatforms as adaptable delivery systems for colon cancer therapy. Further in vivo investigations are warranted to validate their translational and therapeutic potential.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Health Information Technology Department, The Applied College, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
- Pharmacovigilance and Medication Safety Unit, Center of Research Excellence for Drug Research and Pharmaceutical Industries, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
- Department of Pharmaceutics, Institute of Pharmaceutical Education and Research, Wardha Borgaon (Meghe), Wardha 442 001, Maharashtra, India.
- Department of Pharmaceutical Chemistry, College of Pharmacy, National University of Science and Technology, Bousher, Muscat PC 130, Oman.
ORCID-Profile: Aftab Ahmad, Anwar A Alghamdi, Shah Alam Khan
Förderung
- The Ministry of Education and King Abdulaziz University, DSR, Jeddah, Saudi Arabia.
- Institutional Fund Projects
- The Ministry of Education and King Abdulaziz University, DSR, Jeddah, Saudi Arabia
Zitieren
APA
Ahmad, A., Bagwe, D., Khan, S., Dhone, C., Padhare, S., Alghamdi, A. A., & Khan, S. A. (2026). Development of Albumin Nanocarriers for Enhanced Curcumin Delivery and In Vitro Anticancer Activity in Colon Cancer Cells. Pharmaceuticals, 19(6), 872. https://doi.org/10.3390/ph19060872
Vancouver
Ahmad A, Bagwe D, Khan S, Dhone C, Padhare S, Alghamdi AA, et al. Development of Albumin Nanocarriers for Enhanced Curcumin Delivery and In Vitro Anticancer Activity in Colon Cancer Cells. Pharmaceuticals. 2026;19(6):872. doi:10.3390/ph19060872
BibTeX
@article{Ahmad2026,
author = {Ahmad, Aftab and Bagwe, Darshana and Khan, Shagufta and Dhone, Chetna and Padhare, Shilpa and Alghamdi, Anwar A and Khan, Shah Alam},
title = {Development of Albumin Nanocarriers for Enhanced Curcumin Delivery and In Vitro Anticancer Activity in Colon Cancer Cells},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {6},
pages = {872},
doi = {10.3390/ph19060872}
}
EUVIMED